NCT05144997 2025-12-17
Lorlatinib Continuation Study
Pfizer
Phase 4 Active not recruiting
Clinical Trials
5 trialsNCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed
NCT06893354 2025-03-25
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
The First Affiliated Hospital of Guangzhou Medical University
Phase 4 Not yet recruiting
NCT04541706 2024-12-20
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 4 Completed
NCT06282874 2024-02-28
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Not yet recruiting